In the context of AD, mt-Rnr2 has been reported to reduce aggregation and fibrillary formation of the 42-aa form of Abeta (Abeta42) by suppressing the effect of Abeta42 on mononuclear phagocytes and competitively inhibiting the access of FPRL1 to Abeta42 [46]. This evidence concerns the gene APP and Alzheimer disease.